The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response
Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Colombo(University of Milan), Maria Francesca Donato(University of Milan), Valérie Paradis(Inserm), Mirella Fraquelli(University of Padua), Alessio Aghemo, Maria Grazia Rumi(University of Milan), Pierre Bédossa(Régie Autonome des Transports Parisiens (France))
Cited by 147
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|392